Palisade Bio doses first patient in Phase 2b ulcerative colitis trial
Tweet Send to a Friend
Palisade Bio, Inc. (Nasdaq: PALI) announced that the first patient has been dosed in ASCENTRA-UC, its global Phase 2b clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




